Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment

American Journal of Medicine

Volumn 125, Issue 1 SUPPL., 2012, Pages

  Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Antifungal resistance; Azoles; Candida glabrata; Clinical breakpoint; Echinocandins; Epidemiologic cutoff

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CATALASE; CEFTAZIDIME; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; ITRACONAZOLE; MICAFUNGIN; MULTIDRUG RESISTANCE PROTEIN 1; POSACONAZOLE; PYRROLE DERIVATIVE; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC THERAPY; ANTICONVULSANT THERAPY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CEREBROSPINAL FLUID ANALYSIS; CLAVISPORA LUSITANIAE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CROSS RESISTANCE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; DISK DIFFUSION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; EPIDEMIOLOGY; FUNGEMIA; FUNGUS GROWTH; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS DETECTION; VIRUS STRAIN;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CHILD; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; FEMALE; FUNGAL PROTEINS; FURIN; GENE EXPRESSION REGULATION, FUNGAL; GLUCOSYLTRANSFERASES; HUMANS; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; TIME FACTORS; UP-REGULATION;

EID: 84055199809     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.11.001     Document Type: Article

References (81)

1. M.A. Pfaller, D.J. Diekema Epidemiology of invasive mycoses in North America Crit Rev Microbiol 36 2010 1 53
2. M. Cuenca-Estrella, J.L. Rodriguez-Tudela The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro Expert Rev Anti Infect Ther 8 2010 267 276
3. F. Chapeland-Leclerc, C. Hennequin, N. Papon Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient Antimicrob Agents Chemother 54 2010 1360 1362
4. J. Turnidge, D.L. Paterson Setting and revising antibacterial susceptibility breakpoints Clin Microbiol Rev 20 2007 391 408 table of contents (Pubitemid 47175010)
5. E.M. Johnson Issues in antifungal susceptibility testing J Antimicrob Chemother 61 suppl 1 2008 i13 i18
6. C. Lass-Florl, S. Perkhofer, A. Mayr In vitro susceptibility testing in fungi: a global perspective on a variety of methods Mycoses 53 2010 1 11
7. P.G. Pappas, C.A. Kauffman, D. Andes Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
8. Clinical and Laboratory Standards Institute Method for Antifungal Disk Diffusion Suceptibility Testing of Yeasts: Approved Guideline CLSI Document M44-A2 2004 Clinical and Laboratory Standards Institute Wayne, PA
9. Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard CLSI Document M27-A3 2008 Clinical and Laboratory Standards Institute Wayne, PA
10. Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Third informational supplement CLSI Document M27-S3 2008 Clinical and Laboratory Standards Institute Wayne, PA
11. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard CLSI document M38-A2 2008 Clinical and Laboratory Standards Institute Wayne, PA
12. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts Clin Microbiol Infect 14 2008 398 405
13. EUCAST technical note on fluconazole Clin Microbiol Infect 14 2008 193 195
14. EUCAST technical note on voriconazole Clin Microbiol Infect 14 2008 985 987
15. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds Clin Microbiol Infect 14 2008 982 984
16. M. Cuenca-Estrella, M.C. Arendrup, E. Chryssanthou Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) Clin Microbiol Infect 13 2007 1018 1022 (Pubitemid 47382259)
17. M.A. Pfaller, M. Castanheira, D.J. Diekema Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species J Clin Microbiol 48 2010 1592 1599
18. M.A. Pfaller, A. Espinel-Ingroff, L. Boyken Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values J Clin Microbiol 49 2011 845 850
19. M. Pfaller, L. Boyken, R. Hollis Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates J Clin Microbiol 49 2011 1110 1112
20. M.A. Pfaller, D. Andes, D.J. Diekema Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods Drug Resist Updat 13 2010 180 195
21. M.A. Pfaller, D. Andes, M.C. Arendrup Clinical breakpoints for voriconazole and Candida species. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria Diagn Microbiol Infect Dis 70 2011 330 343
22. M.A. Pfaller, D.J. Diekema, D. Andes Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria Drug Resist Updat 14 2011 164 176
23. Clinical and Laboratory Standards Institute Zone diameter interpretative standards, corresponding minimal inhibitory concentration (MIC) interpretative breakpoints, and quality control limits for antifungal disk diffusion suceptibility testing of yeasts; informational supplement CLSI document M44-S3 3rd ed. 2009 Clinical and Laboratory Standards Institute Villanova, PA
24. Clinical and Laboratory Standards Institute Reference method for antifungal disk diffusion testng of non-dermatophyte filamentous fungi; approved guideline CLSI document M51-A 2010 Clinical and Laboratory Standards Institute Villanova, PA
25. Clinical and Laboratory Standards Institute Performance standards for antifungal disk diffusion testng of non-dermatophyte filamentous fungi: informational supplement CLSI document M51-S1 2010 Clinical and Laboratory Standards Institute Villanova, PA
26. B.D. Alexander, T.C. Byrne, K.L. Smith Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents J Clin Microbiol 45 2007 698 706 (Pubitemid 46427680)
27. J.F. Peterson, M.A. Pfaller, D.J. Diekema Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida species J Clin Microbiol 49 2011 1765 1771
28. M.A. Pfaller, D.J. Diekema, G.W. Procop, M.G. Rinaldi Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida species J Clin Microbiol 45 2007 3522 3528 (Pubitemid 350156842)
29. M.A. Pfaller, A. Espinel-Ingroff, R.N. Jones Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole J Clin Microbiol 42 2004 4577 4580 (Pubitemid 39362373)
30. M.A. Pfaller, D.J. Diekema, G.W. Procop, M.G. Rinaldi Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida species J Clin Microbiol 45 2007 796 802 (Pubitemid 46427693)
31. M.A. Pfaller, V. Chaturvedi, D.J. Diekema Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin J Clin Microbiol 46 2008 2155 2159
32. M.A. Pfaller, D.J. Diekema, D.J. Sheehan Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing Clin Microbiol Rev 19 2006 435 447
33. M.C. Arendrup, G. Kahlmeter, J.L. Rodriguez-Tudela, J.P. Donnelly Breakpoints for susceptibility testing should not divide wild-type distributions of important target species Antimicrob Agents Chemother 53 2009 1628 1629
34. C.J. Clancy, V.L. Yu, A.J. Morris Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia Antimicrob Agents Chemother 49 2005 3171 3177 (Pubitemid 41060556)
35. J.H. Rex, M.A. Pfaller, J.N. Galgiani Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards Clin Infect Dis 24 1997 235 247 (Pubitemid 127774263)
36. J.L. Rodriguez-Tudela, B. Almirante, D. Rodriguez-Pardo Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia Antimicrob Agents Chemother 51 2007 3599 3604 (Pubitemid 47519349)
37. M.A. Pfaller, D.J. Diekema, L. Ostrosky-Zeichner Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints J Clin Microbiol 46 2008 2620 2629
38. G. Garcia-Effron, S. Park, D.S. Perlin Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints Antimicrob Agents Chemother 53 2009 112 122
39. D.S. Perlin Resistance to echinocandin-class antifungal drugs Drug Resist Updat 10 2007 121 130 (Pubitemid 47031054)
40. A.J. Zimbeck, N. Iqbal, A.M. Ahlquist FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance Antimicrob Agents Chemother 54 2010 5042 5047
41. Z.A. Kanafani, J.R. Perfect Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact Clin Infect Dis 46 2008 120 128 (Pubitemid 351263573)
42. J. Peman, E. Canton, A. Espinel-Ingroff Antifungal drug resistance mechanisms Expert Rev Anti Infect Ther 7 2009 453 460
43. T.C. White, K.A. Marr, R.A. Bowden Clinical, cellular, and molecular factors that contribute to antifungal drug resistance Clin Microbiol Rev 11 1998 382 402 (Pubitemid 28197359)
44. D.M. MacCallum, A. Coste, F. Ischer Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection Antimicrob Agents Chemother 54 2010 1476 1483
45. S. Katiyar, M. Pfaller, T. Edlind Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility Antimicrob Agents Chemother 50 2006 2892 2894 (Pubitemid 44198725)
46. P.E. Verweij, S.J. Howard, W.J. Melchers, D.W. Denning Azole-resistance in Aspergillus: proposed nomenclature and breakpoints Drug Resist Updat 12 2009 141 147
47. J.W. Baddley, M. Patel, S.M. Bhavnani Association of fluconazole pharmacodynamics with mortality in patients with candidemia Antimicrob Agents Chemother 52 2008 3022 3028
48. B.D. Alexander, W.A. Schell, J.L. Miller Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole Transplantation 80 2005 868 871 (Pubitemid 41443773)
49. C.D. Pfeiffer, G. Garcia-Effron, A.K. Zaas Breakthrough invasive candidiasis in patients on micafungin J Clin Microbiol 48 2010 2373 2380
50. M.A. Pfaller, D.J. Diekema Epidemiology of invasive candidiasis: a persistent public health problem Clin Microbiol Rev 20 2007 133 163 (Pubitemid 46167771)
51. M.A. Pfaller, S.A. Messer, L. Boyken Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location J Clin Microbiol 41 2003 2176 2179 (Pubitemid 36576559)
52. M.A. Pfaller, S.A. Messer, R.J. Hollis Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007 J Clin Microbiol 47 2009 3185 3190
53. J.D. Sobel Changing epidemiology of invasive candidiasis in intensive care unitsmuch ado about nothing? Crit Care Med 36 2008 2188 2189
54. J.D. Sobel Changing trends in the epidemiology of Candida blood stream infections: a matter for concern? Crit Care Med 38 2010 990 992
55. M.A. Pfaller, S.A. Messer, L. Boyken Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida species.: results from a global antifungal surveillance program J Clin Microbiol 46 2008 551 559 (Pubitemid 351231301)
56. Dodgson K.J., Dodgson A.R., Pujol C., et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect.11:364.
57. D.P. Kofteridis, R.E. Lewis, D.P. Kontoyiannis Caspofungin-non- susceptible Candida isolates in cancer patients J Antimicrob Chemother 65 2010 293 295
58. M. Krogh-Madsen, M.C. Arendrup, L. Heslet, J.D. Knudsen Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient Clin Infect Dis 42 2006 938 944
59. M.A. Pfaller, M. Castanheira, S.A. Messer Variation in Candida species Distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009) Diagn Microbiol Infect Dis 66 2010 278 283
60. M.A. Pfaller, M. Castanheira, D.J. Diekema Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method Diagn Microbiol Infect Dis 71 2011 252 259
61. A.I. Aller, E. Martin-Mazuelos, F. Lozano Correlation of fluconazole MICs with clinical outcome in cryptococcal infection Antimicrob Agents Chemother 44 2000 1544 1548 (Pubitemid 30340792)
62. M.E. Brandt, M.A. Pfaller, R.A. Hajjeh Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998 Antimicrob Agents Chemother 45 2001 3065 3069 (Pubitemid 32988829)
63. M.A. Pfaller, S.A. Messer, L. Boyken Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004) J Clin Microbiol 43 2005 2163 2167 (Pubitemid 40656221)
64. M.A. Pfaller, D.J. Diekema, D.L. Gibbs Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing J Clin Microbiol 47 2009 117 123
65. N.P. Govender, J. Patel, M. van Wyk Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 20022003 and 20072008 Antimicrob Agents Chemother 55 2011 2606 2611
66. S.A. Mirza, M. Phelan, D. Rimland The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000 Clin Infect Dis 36 2003 789 794 (Pubitemid 36337986)
67. T. Bicanic, T. Harrison, A. Niepieklo Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution Clin Infect Dis 43 2006 1069 1073 (Pubitemid 44631110)
68. C.C. Bii, K. Makimura, S. Abe Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya Mycoses 50 2007 25 30 (Pubitemid 46046416)
69. J.W. van der Linden, R.R. Jansen, D. Bresters Azole-resistant central nervous system aspergillosis Clin Infect Dis 48 2009 1111 1113
70. D.W. Denning Therapeutic outcome in invasive aspergillosis Clin Infect Dis 23 1996 608 615 (Pubitemid 26304513)
71. S. Schwartz, M. Ruhnke, P. Ribaud Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 2005 2641 2645 (Pubitemid 41510735)
72. T.J. Walsh, E.J. Anaissie, D.W. Denning Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 2008 327 360 (Pubitemid 351265310)
73. J.L. Rodriguez-Tudela, L. Alcazar-Fuoli, E. Mellado Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus Antimicrob Agents Chemother 52 2008 2468 2472 (Pubitemid 351915677)
74. E. Snelders, H.A. van der Lee, J. Kuijpers Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism PLoS Med 5 2008 e219
75. M.C. Arendrup, S. Perkhofer, S.J. Howard Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins Antimicrob Agents Chemother 52 2008 3504 3511
76. S.J. Howard, I. Webster, C.B. Moore Multi-azole resistance in Aspergillus fumigatus Int J Antimicrob Agents 28 2006 450 453 (Pubitemid 44740492)
77. P.E. Verweij, E. Mellado, W.J. Melchers Multiple-triazole-resistant aspergillosis N Engl J Med 356 2007 1481 1483
78. K.L. Mortensen, E. Mellado, C. Lass-Florl Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain Antimicrob Agents Chemother 54 2010 4545 4549
79. P.E. Verweij, E. Snelders, G.H. Kema Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 9 2009 789 795
80. A. Bueid, S.J. Howard, C.B. Moore Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009 J Antimicrob Chemother 65 2010 2116 2118
81. S.R. Lockhart, J.P. Frade, K.A. Etienne Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS Global Surveillance is primarily due to the TR/L98H mutation in the cyp51A gene Antimicrob Agents Chemother 55 2011 4465 4468